Modality
Radioligand
MOA
JAK1/2i
Target
RET
Pathway
Checkpoint
Endometrial CaHSTTR Amyloidosis
Development Pipeline
Preclinical
Sep 2019
→ Apr 2029
PreclinicalCurrent
NCT08457379
945 pts·Endometrial Ca
2023-10→2026-06·Active
NCT03575505
783 pts·Endometrial Ca
2019-09→2029-04·Recruiting
1,728 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-152mo awayInterim· Endometrial Ca
2029-04-113.0y awayInterim· Endometrial Ca
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Recruit…
Preclinical
Active
Catalysts
Interim
2026-06-15 · 2mo away
Endometrial Ca
Interim
2029-04-11 · 3.0y away
Endometrial Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08457379 | Preclinical | Endometrial Ca | Active | 945 | PASI75 |
| NCT03575505 | Preclinical | Endometrial Ca | Recruiting | 783 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |